ClinicalTrials.gg
CompletedNCT07540884Updated Oct 7, 2026

Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops

An interventional study of Tears Naturale Free lubricating eye drops and Tears Naturale II lubricating eye drops in Dry Eye Disease, sponsored by Alcon Research. Completed at 6 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Alcon Research (part of Alcon) · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Dry Eye Syndromes by Alcon — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · Alcon.

Enrollment
23rd of 88
132 · median 65
Started
2026
with 2 others
No phase
64 of 92
none open now
Registered
91st of 92
by date

Among the 92 studies in Dry Eye Syndromes by Alcon, this one is the 23rd largest by enrollment of the 88 interventional ones that give a count, is one of 3 that started in 2026, is one of 64 with no phase, and was the 91st registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 92 studies in Dry Eye Syndromes by Alcon is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Dry Eye Syndromes by Alcon, or all of them as a file.
02

Study summary

The purpose of this post-market clinical follow-up (PMCF) study is to describe the effectiveness and safety of Tears Naturale® Free and Tears Naturale® II lubricant eye drops in subjects experiencing dry eye (DE) symptoms.

Read the detailed description

Each subject's participation will last approximately 30 days and include three scheduled visits: a screening/baseline clinic visit on Day 1 (Visit 1), a telephone follow-up visit on Day 15 (-2/+5 days) (Visit 2), and an in-office visit on Day 30 (-2/+5 days) (Visit 3).

This study will be conducted in Canada.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

Keywords

  • lubricating eye drops
  • dry eyes
  • artificial tears
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to read, understand, and sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved form in English or French.
  • Able to attend all study visits as required as per protocol.
  • Mild to moderate dry eye disease.
  • Willing to discontinue use of all habitual artificial tear supplements and use only the study device for the entire study duration.
  • Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

  • Any known allergic reactions to the study products or its ingredients.
  • Ocular injury to either eye in the past 3 months prior to screening.
  • Ocular surgery within the previous 6 months or ocular surgery planned during the study.
  • Use of any systemic medication known to cause dry eye for less than 1 month before the Screening/Baseline visit.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Tears Naturale Free

    One to two drops of artificial tears per eye as needed for 30 days (-2/+5 days)

    Other: Tears Naturale Free lubricating eye drops

  • Experimental
    Tears Naturale II

    One to two drops of artificial tears per eye as needed for 30 days (-2/+5 days)

    Other: Tears Naturale II lubricating eye drops

Interventions

  • OtherTears Naturale Free lubricating eye drops

    Commercially available, preservative free, artificial tear product containing dextran 70 and hypromellose. Artificial tear products are designed to relieve dryness and irritation by supplementing and stabilizing the tear film.

  • OtherTears Naturale II lubricating eye drops

    Commercially available, artificial tear product containing dextran 70 and hypromellose with a gentle preservative for multi-dose use. Artificial tear products are designed to relieve dryness and irritation by supplementing and stabilizing the tear film.

06

What researchers measure

Primary outcomes

  1. Mean Impact of Dry Eye on Everyday Life - Symptom Bother Module (IDEEL - SB) Score

    The IDEEL SB module is a 20-question, patient-reported outcome questionnaire that assesses the subject's symptoms of dry eye. For each question, the subject selected a single response for both eyes, where 0="None of the time" (Q1) or "I did not have this symptom/Not Applicable" (Q2-20) to 4="All of the time" (Q1) or "Very Much" (Q2-20). The overall Symptom Bother score is calculated as the mean value of the non-missing item scores (Q1-20) multiplied by 25, for an overall resultant score ranging from 0 to 100. Higher scores indicate greater symptom bother.

    Time frame: Screening/Baseline Visit (Day 1), Day 30

07

Study locations

6 sites
  • Integra Eyecare Centre
    Burnaby, British Columbia V5E 1G3, Canada
  • The Medical Arts Health Research Group
    Kelowna, British Columbia V1Y 4N7, Canada
  • Eyes on Sheppard
    North York, Ontario M2N 3A1, Canada
  • Dr. Shalu Pal & Associates
    Toronto, Ontario M5R 2A5, Canada
  • Institut de L'Oeil des Laurentides
    Boisbriand, Quebec J7H 0E8, Canada
  • Hopital de Chicoutimi and LASIK MD
    Chicoutimi, Quebec G7H 7W8, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Sep 2026, 3 months.

Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 3 months is below that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 21, 2026
StartActual
Jun 4, 2026
Primary completionActual
Sep 14, 2026
CompletionActual
Sep 14, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 7, 2026
Enrollment
120 (estimated)→132 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Completed
    Enrollment 120 (estimated)→132 (actual)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07540884
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Jun 4, 2026
Primary completion
Sep 14, 2026
Completion
Sep 14, 2026
Last update
Oct 7, 2026

Study contacts

Clinical Trial Lead, Dry Eye
study director · Alcon Research, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion